-
Xinzeyuan Medical Technology Secures Over RMB 100 Million in Series B Financing
•
Xinzeyuan Medical Technology Co., Ltd, a Hangzhou-based micro invasive medical device supply chain platform, has reportedly secured over RMB 100 million (USD 13.8 million) in a Series B financing round. The round was led by Qiming Venture Partners, with Silicon Paradise also participating in the funding. The company plans to…
-
Singlera Genomics Secures Over RMB 100 Million in Strategic Financing to Boost R&D and Commercialization
•
Singlera Genomics Inc., a genetic testing and molecular diagnostics company with operations in San Diego, California, and in Shanghai and Yangzhou, China, has reportedly secured over RMB 100 million in a strategic financing round. The funding was led by Yangzhou Guojin, Longchuan Holding, and other municipal state-owned funds based in…
-
Chengdu-Based Vaccine Specialist Maxvax Biotechnology Raises USD 41.3 Million in Latest Funding Round
•
Maxvax Biotechnology, a leading vaccine-focused biotech company headquartered in Chengdu, has successfully closed its Series C+ financing round, securing over RMB 300 million (USD 41.3 million). This latest funding round was spearheaded by IDG Capital, with significant participation from Hankang Capital and Qianhai Ark Asset Management. The capital raised in…
-
Moon Biotech Secures Exclusive State-Owned Fund Investment in Series C+ Round
•
Moon (Guangzhou) Biotech Co., Ltd, a leading microbiome platform company based in China, has reportedly secured RMB 300 million (USD 41.3 million) in a Series C+ financing round. The funding was exclusively provided by SDIC JULI Investment, a state-owned investment fund. Established in 2015, Moon is recognized for possessing the…
-
TowardPi Medical Secures RMB 200 Million in Series D Financing Led by Matrix Partners
•
TowardPi (Beijing) Medical Technology Ltd, a Chinese medical technology company, has reportedly secured RMB 200 million in a Series D financing round. The round was led by Matrix Partners, with participation from GTJA Investment and other investors. Established in 2017, TowardPi Medical’s core technical team comprises numerous graduates from Tsinghua…
-
Shanghai’s Phrontline Biopharma Secures Over RMB 100 Million in Pre-Series A Funding for ADC Development
•
Shanghai-based antibody drug conjugate (ADC) specialist Phrontline Biopharma has reportedly secured over RMB 100 million (USD 13.8 million) in a pre-Series A financing round, with funds exclusively provided by Decheng Capital. The capital raised will be directed towards bolstering research and development efforts, pre-clinical development, and the enhancement of its…
-
Aidea Pharmaceutical to Boost Stake in Nanda Pharmaceutical to 51.1256%
•
Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a pharmaceutical company based in China, is poised to acquire a 31.161% stake in fellow Chinese firm Nanjing Nanda Pharmaceutical Co., Ltd for a consideration of RMB 149.57 million (USD 20.6 million). Aidea had previously secured a 19.9646% stake in Nanda Pharma in…
-
Jiangsu Jibeier Pharm Completes Private Placement to Fund R&D Center on STAR Market
•
Jiangsu Jibeier Pharm Co., Ltd (SHA: 688566), a Chinese pharmaceutical company, has announced the successful completion of a private placement of 7,446,889 shares at a price of RMB 26.61 per share. The shares will be listed on the Science and Technology Innovation Board (STAR), which is hosted by the Shanghai…
-
Fosun Pharma to Take Henlius Private in Deal Valued at HKD 5.407 Billion
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced plans to take its subsidiary Shanghai Henlius Biotech Co., Ltd (HKG: 2696) private. According to a stock exchange announcement from the China-based firm, Fosun currently holds 323.7 million shares of Henlius, representing 59.56% of the company’s total shares.…
-
AnDiConBio Secures Over RMB 200 Million in Series A Financing to Advance Respiratory and Pain Therapies
•
AnDiConBio, a Zhejiang-based innovative pharmaceutical company specializing in respiratory infections and pain management, has reportedly secured over RMB 200 million in a Series A financing round. The round was led by Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096), Huajin Investment, and Huajin Dadao Investment, with participation from Cowin Capital, Wenzhou…
-
METiS Therapeutics Secures USD 100 Million in Series C Financing to Advance AI Drug Delivery
•
METiS Therapeutics, a biopharmaceutical company based in Cambridge, Massachusetts, has secured USD 100 million in a Series C financing round. The round was led by CICC Capital, with additional investment from China Taiping Insurance. This latest funding round brings the total capital raised by the Sino-US firm to USD 300…
-
Ascentage Pharma’s THDBH120 Receives NMPA Approval for Phase Ib Clinical Trial
•
Ascentage Pharma (HKG: 6855), a biopharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) for its Phase Ib clinical study of GLP-1/GIP dual-targeted receptor agonist THDBH120 as a hypoglycemic therapy. THDBH120, which is being developed to treat type 2 diabetes…
-
DK Medical Technology Secures ‘Hundreds of Millions’ in Series E Financing for Expansion
•
DK Medical Technology Co. Ltd., a Suzhou-based developer of vascular intervention balloon products, has reportedly secured “hundreds of millions” of renminbi in a Series E financing round. The round was co-led by Legend Capital and Qiming Venture Partners, with additional investments from existing shareholders. The funds will be utilized to…
-
Shanghai Fosun Pharmaceutical Sells Stake in Gland Pharma for USD 211 Million
•
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the sale of a 6.01% stake in its India-based subsidiary, Gland Pharma Ltd (BOM: 543245), through bulk trading. The transaction raised INR 7.541 billion (USD 90 million) pre-tax, or approximately USD 211 million pre-tax. Following the completion of…
-
Grifols Completes Sale of 20% Stake in Shanghai RAAS to Haier Group for RMB 12.5 Billion
•
Grifols AS (NASDAQ: GRFS), a Spain-based global leader in the production of blood products, has announced the completion of a significant transaction where it sold a 20% stake in Shanghai RAAS Blood Products Co., Ltd (SHE: 002252) to Haier Group, a Chinese electronics and appliances conglomerate, for RMB 12.5 billion…
-
3SBio Secures Long-Term Financing from IFC for Manufacturing and Global Expansion
•
3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, is slated to receive long-term loan credit from the International Finance Corporation (IFC), with the funds designated for the construction of manufacturing facilities and the development of overseas business. This development signifies that 3SBio, the first Chinese biopharmaceutical enterprise to…
-
CATUG Biotechnology Secures Nearly RMB 100 Million in Latest Financing Round to Expand Globally
•
CATUG Biotechnology, a cutting-edge company in the nucleic acid and gene therapy sector, has announced the successful completion of a new financing round, raising nearly RMB 100 million (USD 13.8 million). This funding round was led by prominent investors Yifeng Capital and Zhiyi Investment, with additional participation from Yuanhe Holdings…
-
Neusoft IntelliRay Secures Over RMB 100 Million in Series C Funding Round
•
Neusoft IntelliRay Technology Co., Ltd, a medical technology company based in Shenyang, has successfully closed a Series C funding round, securing over RMB 100 million (approximately USD 13.8 million). The financing was spearheaded by Leli PE Capital and Neusoft Capital, with the funds earmarked for the advancement and market expansion…
-
Ronovo Surgical Secures Over RMB 300 Million in Series B to Globalize Surgical Robot
•
Shanghai-based surgical robotics specialist, Ronovo Surgical, has reportedly raised over RMB 300 million (USD 41.3 million) in a Series B financing round. The funding round was co-led by Guolian Group and Ince Capital, with contributions from King Star Med LP and existing investor LongRiver. The capital will be utilized to…
-
Cellbri Bio Secures Nearly RMB 200 Million in Series B Financing to Boost CGT Commercialization
•
Shenzhen Cellbri Bio-Innovation Technology Co., Ltd, a prominent player in China’s cell and gene therapy (CGT) sector, has reportedly secured nearly RMB 200 million in a Series B financing round. The round was led by 3E Bioventures, with participation from HongSheng Capital and existing investors including Beijing Shuimu Guoding Investment,…
